Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2023; 15(04): 510-517
DOI: 10.1055/s-0043-1768630
Original Article

Effect of ABCA1-R219K Polymorphism in Serum Lipid Parameters in Patients under Statin Therapy Visiting Tertiary Cardiac Center of Nepal

Sapana Ghimire 
1   Shahid Dharma Bhakta National Transplant Center, Bhaktpur, Nepal
,
Binod Kumar Yadav
2   Maharajgunj Medical Campus, Institute of Medicine, Kathmandu, Nepal
,
Sweta Shrestha
3   Department of Laboratory, Nicklaus Children's Hospital, Miami, Florida, United States
,
Jivan Shakya 
4   Kathmandu University School of Medical Sciences, Banepa, Nepal
,
Chandra Mani Poudel 
5   Manmohan Cardiothoracic Vascular and Transplant Center, Kathmandu, Nepal
,
Eans Tara Tuladhar 
2   Maharajgunj Medical Campus, Institute of Medicine, Kathmandu, Nepal
,
Vijay Kumar Sharma
2   Maharajgunj Medical Campus, Institute of Medicine, Kathmandu, Nepal
,
Mithilesh Raut 
2   Maharajgunj Medical Campus, Institute of Medicine, Kathmandu, Nepal
,
Aseem Bhattarai 
2   Maharajgunj Medical Campus, Institute of Medicine, Kathmandu, Nepal
,
Krishna Das Manandhar
6   Department of Biotechnology, Tribhuvan University Central, Kathmandu, Nepal
,
Vivek Pant 
7   Samyak Diagnostic Center, Lalitpur, Nepal
,
Deependra Shrestha 
8   ER-Lab, TU Teaching Hospital, Kathmandu, Nepal
› Author Affiliations Funding This study was partially supported by Nepal Health Research Council under postgraduate thesis grant award (Grant Award no.2075-76-Postgraduate thesis grant) to Sapana Ghimire.
› Further Information
   Permissions and Reprints

Abstract

Introduction ATP-binding cassette transporter A1 (ABCA1) encoded by ABCA1 gene is one of the important protein involved in lipid metabolism. The effect of statin therapy on dyslipidemia varies among individuals and it may be due to different genetic polymorphism. The R219K polymorphism of ABCA1 gene is found to have a significant role in the response of statin.

Objective This study was designed to evaluate the effect of R219K polymorphism in lipid-lowering action of statin in patients with dyslipidemia.

Material and Methods This study was conducted in 88 patients. Blood samples were taken from patients before and at the end of 3 months of statin use and were analyzed for lipid profile. Whole blood was analyzed for R219K Polymorphism using polymerase chain reaction-restriction fragment length polymorphism.

Results R219K polymorphism was associated with significant percentage reduction of serum triglyceride/high-density lipoprotein (TG/HDL) ratio and total cholesterol/high-density lipoprotein (TC/HDL) ratio in atorvastatin users. However, there was no significant association of polymorphism with change in serum TC, HDL-C, LDL-C, TG, and very low-density lipoprotein (VLDL). Among KK genotype individuals, value of TG, VLDL, TG/HDL, and TC/HDL were significantly lower than in RR genotypes. Also, TG/HDL and TC/HDL were significantly lower in RK genotype than in RR. Treatment of dyslipidemia with statin was found to be comparatively better in patients having the genotypes KK and RK.

Conclusion Our study demonstrated association of R219K polymorphism with the significant reduction of TG/HDL and TC/HDL and particularly the KK genotype was associated with significant improvement of lipid parameters following atorvastatin treatment.

Keywords

R219K polymorphism - PCR-RFLP - lipid profile - single-nucleotide polymorphisms - dyslipidemia - atorvastatin - statin therapy

Data Availability

All the data used and/or analyzed in this study can make available from the corresponding author on request.


Patient Consent

The informed consent was obtained from all the individual patients.


Ethical Approval

This study was approved by the Institutional Review committee (IRC), Institute of Medicine (IOM), Kathmandu, Nepal (IRC reference number: 320(6–11-E) 2/074/075).


Consent for Publication

I, Binod Kumar Yadav, corresponding author of this manuscript give full consent for publication on behalf of all co-authors.


Authors' Contribution

S.G. performed laboratory work, statistical analysis, and manuscript writing. BKY helped in designing the study, analysis of the data, and writing of the manuscript and proof reading. J.S. contributed to laboratory work standardization, data analysis, and proof reading. S.S. and D.S. supported in laboratory work. V.K.S., E.T.T., M.R., and A.B. conceived the study and participated in the design and coordination of the study. K.D.M., C.M.P., and V.P. read and approved the final manuscript.




Publication History

Received: 22 September 2022

Accepted: 26 February 2023

Article published online:
03 July 2023

© 2023. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Kang YJ, Wang HW, Cheon SY, Lee HJ, Hwang KM, Yoon HS. Associations of obesity and dyslipidemia with intake of sodium, fat, and sugar among Koreans: a qualitative systematic review. Clin Nutr Res 2016; 5 (04) 290-304
    CrossrefPubMedGoogle Scholar
  • 2 Lin C-F, Chang Y-H, Chien S-C, Lin Y-H. Yeh H-Y. Epidemiology of dyslipidemia in the Asia Pacific region. Int J Gerontol 2018; 12 (01) 2-6
    CrossrefGoogle Scholar
  • 3 Qi L, Ding X, Tang W. et al. Prevalence and risk factors associated with dyslipidemia in Chongqing, China. Int J Environ Res Public Health 2015; 12 (10) 13455-13465
    CrossrefPubMedGoogle Scholar
  • 4 Sukhorukov V, Karagodin V, Orekhov AN. Modern methods of diagnosis dyslipidemia. Patol Fiziol Eksp Ter 2016; 60 (01) 65-72
    PubMedGoogle Scholar
  • 5 Parhofer KJDI. Update dyslipidemia. 2013;54(9):1089–103
    Google Scholar
  • 6 Jacobson TA, Ito MK, Maki KC. et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol 2015; 9 (02) 129-169
    CrossrefPubMedGoogle Scholar
  • 7 Bonfim MR, Oliveira ASB, Amaral SLd, Monteiro HL. Treatment of dyslipidemia with statins and physical exercises: recent findings of skeletal muscle responses. Arq Bras Cardiol 2015; 104: 324-331
    PubMedGoogle Scholar
  • 8 Clark LT. Treating dyslipidemia with statins: the risk-benefit profile. Am Heart J 2003; 145 (03) 387-396
    CrossrefPubMedGoogle Scholar
  • 9 Ramkumar S, Raghunath A, Raghunath S. Statin therapy: review of safety and potential side effects. Acta Cardiol Sin 2016; 32 (06) 631
    PubMedGoogle Scholar
  • 10 Mandal CC. High cholesterol deteriorates bone health: new insights into molecular mechanisms. Front Endocrinol (Lausanne) 2015; 6: 165
    CrossrefPubMedGoogle Scholar
  • 11 Jones PH, McKenney JM, Karalis DG, Downey J, Journal NIJAH. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am Heart J 2005; 149 (01) e1-e8
    CrossrefPubMedGoogle Scholar
  • 12 Bhattarai AK, Acharya A, Karki PK. Use of statins as lipid lowering agent in hypercholesterolemia in a tertiary care hospital: a descriptive cross-sectional study. J Nepal Med Assoc 2020; 58 (232) 1031-1035
    CrossrefPubMedGoogle Scholar
  • 13 Kansu B, Lang D. . Genetic polymorphisms as predictive markers for statin therapy: a route to improved cardiovascular patient outcomes? JBHTIJoSR 2017;10
  • 14 Ergen A, Isbir S, Tekeli A, Isbir T. Investigation of ABCA1 C69T and G-191C polymorphisms in coronary artery disease. In Vivo 2008; 22 (02) 187-90
    PubMedGoogle Scholar
  • 15 Guo Z, Wu P, Xie D, Wang Q, Liu Y, Cha Z. et al. A new discovered ABCA1 gene polymorphisms and the association of ABCA1 SNPs with coronary artery disease and plasma lipids in Chinese population. 2011 ;26(4):179–90
    PubMedGoogle Scholar
  • 16 Ghaznavi H, Aali E, Soltanpour MS. Association study of the ATP-binding cassette transporter A1 (ABCA1) Rs2230806 genetic variation with lipid profile and coronary artery disease risk in an Iranian population. Open Access Maced J Med Sci 2018; 6 (02) 274-279
    CrossrefPubMedGoogle Scholar
  • 17 Genvigir FDV, Soares SA, Hirata MH. et al. Effects of ABCA1 SNPs, including the C-105T novel variant, on serum lipids of Brazilian individuals. Chin Chim Acta 2008; 389 (1–2): 79-86
    CrossrefPubMedGoogle Scholar
  • 18 Lutucuta S, Ballantyne CM, Elghannam H, Gotto Jr AM, Marian AJ. Novel polymorphisms in promoter region of ATP binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy. Circ Res 2001; 88 (09) 969-73
    CrossrefPubMedGoogle Scholar
  • 19 Ceccanti M, Cambieri C, Frasca V, Onesti E, Biasiotta A, Giordano C. et al. A novel mutation in ABCA1 gene causing Tangier disease in an Italian family with uncommon neurological presentation. Front Neurol 2016; 7: 185
    CrossrefPubMedGoogle Scholar
  • 20 Saleheen D, Khanum S, Haider SR, Nazir A, Ahmad U, Khalid H. et al. A novel haplotype in ABCA1 gene effects plasma HDL-C concentration. Int J Cardiol 2007; 115 (01) 7-13
    CrossrefPubMedGoogle Scholar
  • 21 Wang N, Silver DL, Thiele C, Tall AR. ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem 2001; 276 (26) 23742-7
    CrossrefPubMedGoogle Scholar
  • 22 Zargar S, Wakil S, Mobeirek AF, Al-Jafari AA. Involvement of ATP-binding cassette, subfamily A polymorphism with susceptibility to coronary artery disease. Biomed Rep 2013; 1 (06) 883-8
    CrossrefPubMedGoogle Scholar
  • 23 Wu Y, Bai H, Liu R, Liu Y, Liu B. Analysis of ATP binding cassette A1 gene R219K polymorphism in patients with endogenous hypertriglyceridemia in Chinese population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2007; 24 (02) 177-181
    PubMedGoogle Scholar
  • 24 Pontoriero AC, Trinks J, Hulaniuk ML, Caputo M, Fortuny L, Pratx LB. et al. Influence of ethnicity on the distribution of genetic polymorphisms associated with risk of chronic liver disease in South American populations. 2015;16(1):1–8
    Google Scholar
  • 25 May S. Rapid Extraction of High Quality DNA from Whole Blood Stored at 4°C for Long Period
  • 26 Kolovou V, Marvaki A, Boutsikou M, Vasilopoulos G, Degiannis D, Marvaki C. et al. Effect of ATP-binding cassette transporter A1 (ABCA1) gene polymorphisms on plasma lipid variables and common demographic parameters in Greek nurses. 2016 ;10:233
    PubMedGoogle Scholar
  • 27 Pradeepa R, Mohan V. Epidemiology of Dyslipidemia in India. 2017
    PubMedGoogle Scholar
  • 28 Kopin L. Lowenstein CJJAoim. Dyslipidemia. 2017; 167 (11) ITC81-ITC96
    Google Scholar
  • 29 Sorace P, LaFontaine T, Thomas TR. Know the risks: lifestyle management of dyslipidemia. ACSM's Health Fit J 2006; 10 (04) 18-25
    CrossrefGoogle Scholar
  • 30 Zineh I. Pharmacogenetics of response to statins. Curr Atheroscler Rep 2007; 9 (03) 187-194
    CrossrefPubMedGoogle Scholar
  • 31 Clee SM, Zwinderman AH, Engert JC. et al. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation 2001; 103 (09) 1198-1205
    CrossrefPubMedGoogle Scholar
  • 32 Mantaring M, Rhyne J, Hong SH, Miller M. Genotypic variation in ATP-binding cassette transporter-1 (ABCA1) as contributors to the high and low high-density lipoprotein-cholesterol (HDL-C) phenotype. Transl Res 2007; 149 (04) 205-210
    CrossrefPubMedGoogle Scholar
  • 33 Akao H, Polisecki E, Schaefer EJ. et al. ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment. Atherosclerosis 2014; 235 (01) 176-181
    CrossrefPubMedGoogle Scholar
  • 34 Li J, Wang LF, Li ZQ, Pan W. Effect of R219K polymorphism of the ABCA1 gene on the lipid-lowering effect of pravastatin in Chinese patients with coronary heart disease. Clin Exp Pharmacol Physiol 2009; 36 (5-6): 567-570
    CrossrefPubMedGoogle Scholar
  • 35 Mokuno J, Hishida A, Morita E. et al. ATP-binding cassette transporter A1 (ABCA1) R219K (G1051A, rs2230806) polymorphism and serum high-density lipoprotein cholesterol levels in a large Japanese population: cross-sectional data from the Daiko Study. Endocr J 2015; •••: EJ14-EJ0577
    Google Scholar
  • 36 Maruyama C, Imamura K, Teramoto T. Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia. J Atheroscler Thromb 2003; 10 (03) 186-191
    CrossrefPubMedGoogle Scholar